FDA says Zicam nasal spray can cause loss of smell

Consumers should stop using Zicam Cold Remedy
nasal gel and related products because they can permanently damage
the sense of smell, federal health regulators said Tuesday.

The over-the-counter products contain zinc, an ingredient
scientists say may damage nerves in the nose needed for smell. The
other products affected by the Food and Drug Administration's
announcement are adult and kid-size Zicam Cold Remedy Nasal Swabs.

The FDA says about 130 consumers have reported a loss of smell
after using Matrixx Initiatives' Zicam products since 1999. Shares
of the Scottsdale, Ariz.-based company plunged to a 52-week low
after the FDA announcement, losing more than half their value.

"Loss of the sense of smell is potentially life threatening and
may be permanent," said Dr. Charles Lee, of FDA's compliance
division. "People without the sense of smell may not be able to
detect dangerous life situations, such as gas leaks or something
burning in the house."

Matrixx defended the safety of its products, but said late
Tuesday it will withdraw Zicam Cold Remedy Swabs and Zicam Cold
Remedy Gel from the market.

The FDA said Zicam Cold Remedy was never formally approved
because it is part of a small group of remedies that are not
required to undergo federal review before launching. Known as
homeopathic products, the formulations often contain herbs,
minerals and flowers.

A warning letter issued to Matrixx on Tuesday asked the company
to stop marketing its zinc-based products, but the agency did not
issue a formal recall. Instead, regulators said Matrixx would have
to submit safety and effectiveness data on the drug.

"The next step, if they wish to continue marketing Zicam
intranasal zinc products, is for them to come in and seek FDA
approval," said Deborah Autor, director of FDA's drug compliance
division.

The agency is requiring formal approval now because of the
product's safety issues, she added.

"It won't bring my smell back, but at least I feel like there's
some justice that's starting to take place," said David
Richardson, of Greensboro, N.C., who lost his sense of smell after
taking Zicam for a cold in 2005. He said he hopes the product will
be formally banned.

Medical records appear to support Richardson's claim that his
lost sense of smell was linked to using Zicam.

The global market for homeopathic drugs is about $200 million
per year, according to the American Association of Homeopathic
Pharmacists. The group's members include companies like
Nutraceutical International Corp. and Natural Health Supply.

Matrixx has settled hundreds of lawsuits connected with Zicam in
recent years, but says on its Web site: "No plaintiff has ever won
a court case, because there is no known causal link between the use
of Zicam Cold Remedy nasal gel and impairment of smell."

The company said in a statement Tuesday that the safety of Zicam
Cold Remedy is "supported by the cumulative science and has been
confirmed by a multidisciplinary panel of scientists." Matrixx
said it will comply with the FDA's requirements, but will seek a
meeting with the agency to "vigorously defend its scientific
data."

But government scientists say they are unaware of any data
supporting Zicam's labeling, which claims the drug reduces cold
symptoms, including "sore throat, stuffy nose, sneezing, coughing
and congestion."

The products accounted for about 40 percent of Matrixx's $111.6
million in sales last year.

Health officials said they have asked Matrixx executives to turn
over more than 800 consumer complaints concerning lost smell that
the company has on file. A 2007 law began requiring manufacturers
to report such problems, but FDA regulators declined to say Tuesday
whether the company broke the law.

The 130 reports received by the FDA came entirely from
physicians and patients, not the manufacturer.

Regulators said the relatively small number of complaints
accounted for the agency's lengthy investigation.

"FDA doesn't take action against drug products without
evaluating all of the circumstances surrounding the issues with the
product," Lee said.

Shares of Matrixx Initiatives Inc. plummeted $13.46, or 70
percent, to $5.78 Tuesday. The company said based on the FDA's
recommendation, consumers should discard any unused product or
contact Zicam at 1-877-942-2626 or www.zicam.com to request a
refund.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
KOLO-TV 4850 Ampere Drive Reno, NV 89502
Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 48214292 - kolotv.com/a?a=48214292
Gray Television, Inc.